A Phase I Study of Immune Checkpoint Inhibition (Anti-CTLA4 and/or Anti-PD-L1) in Combination With Radiation Therapy in Patients With Unresectable and Non-metastatic Pancreatic Cancer
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 03 Apr 2019 Planned End Date changed from 1 Feb 2020 to 4 Mar 2019.
- 03 Apr 2019 Planned primary completion date changed from 1 Feb 2019 to 4 Mar 2019.
- 03 Apr 2019 Planned initiation date changed from 1 Aug 2016 to 7 Aug 2016.